NDAORALSOLUTION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
NORLIQVA (amlodipine) by BrilliantStrings Therapeutics is calcium channel antagonists [moa]. First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLIQVA is an oral amlodipine solution approved in 2022 for hypertension and angina, representing a reformulated delivery of a well-established dihydropyridine calcium channel blocker. It works by inhibiting calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced peripheral resistance. The solution formulation offers an alternative administration route to traditional tablets.
$0.299MPart D
Peak14.4 years to LOEEarly-stage commercial maturation with modest Medicare adoption suggests a smaller team focused on market penetration and healthcare provider education.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Started Mar 2026
3,500 enrolled
Hypertension
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
Started May 2024
48 enrolled
Healthy Volunteer
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
Started May 2024
396 enrolled
Arterial HypertensionHTN
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
Started Apr 2024
718 enrolled
Hypertension
Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
Started Apr 2023
409 enrolled
Arterial HypertensionHTN
Worked on NORLIQVA at BrilliantStrings Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.